STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of ...
A Racine man and woman are facing multiple felony charges after a drug bust. A 1-year-old and a 6-year-old also tested positive for cocaine in their bodies. It all started with a confidential ...
Abstract: The current pronunciation scoring based on Goodness of Pronunciation (GOP) uses posterior probabilities of the Acoustic Models. Such algorithms suffer from generalization since they are ...
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2025 Earnings Call Transcript February 26, 2026 Collegium Pharmaceutical, Inc. misses on earnings expectations. Reported EPS is $0.4273 EPS, ...
Tupper reaffirmed 2026 product revenue guidance of $805 million to $825 million, citing a 4% increase year-over-year, driven by Jornay growth and durable revenues from the pain portfolio. Jornay ...
Greetings. Welcome to the Collegium Pharmaceutical Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] Please note, this conference call is being recorded. I'll now ...
Collegium Pharmaceutical Inc. (NASDAQ:COLL) presented its fourth quarter and full-year 2025 results on February 26, 2026, showcasing a year of significant transformation despite falling short of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results